Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Financings in Brief: Cambridge Heart

This article was originally published in The Gray Sheet

Executive Summary

Cambridge Heart: Developer of the CH 2000 system files a registration statement with the Securities and Exchange Commission for an initial public offering of 3 mil. shares, expected to be priced between $11 and $13 per share. The company plans to offer 2.4 mil. shares in the U.S. and 600,000 shares in a concurrent international offering. Underwriters Goldman Sachs and Bear Stearns have an over-allotment option to purchase 450,000 additional shares. Proceeds from the offering will fund research and development, clinical trials, purchase of capital equipment, expansion of sales and marketing efforts, working capital and general corporate purposes, the company says.



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts